A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

This is an early-phase (Phase I) study testing the safety, tolerability, and dosing of an experimental cancer drug in people with advanced solid tumors that have stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older with an advanced solid tumor that is resistant to or has stopped responding to standard treatment - Your tumor can be measured on a scan - Your general health score is 0 or 1 (fully active or able to do light work) - Your blood counts, liver, kidney, and clotting function are within acceptable ranges - Your expected survival is more than 3 months - You are not pregnant or breastfeeding and are willing to use contraception if needed **You may NOT be eligible if...** - You have received cancer treatment (chemo, targeted therapy, immunotherapy) within the past 4 weeks - You have significant heart, kidney, or liver disease - You have had major surgery within 4 weeks - You have active brain metastases (cancer that has spread to the brain) - You have a serious bleeding or clotting disorder Talk to your doctor to see if this trial is right for you.